

JAK/STAT signaling in hematological malignancies

Oncogene

32, 2601-2613

DOI: [10.1038/onc.2012.347](https://doi.org/10.1038/onc.2012.347)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Generic, Hands-On Control System Laboratory. , 1988, , .		4
2	CramrRao lower bound for tracking multiple targets. , 2009, , .		0
3	Session 15: E-learning. , 2011, , .		0
4	Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. Journal of Cellular and Molecular Medicine, 2013, 17, 1218-1235.	1.6	49
5	Biosensors in Clinical Practice: Focus on Oncohematology. Sensors, 2013, 13, 6423-6447.	2.1	61
6	The role of cytokines in the initiation and progression of myelofibrosis. Cytokine and Growth Factor Reviews, 2013, 24, 133-145.	3.2	128
7	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. PLoS Genetics, 2013, 9, e1003997.	1.5	110
8	eIF4B Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by <i>Abl</i> Oncogenes. Cancer Research, 2013, 73, 4898-4908.	0.4	65
9	Association of cyclin D and estrogen receptor β with hepatocellular adenomas of female mice under chronic endoplasmic reticulum stress. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 576-583.	1.4	11
10	Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20599-20604.	3.3	15
11	Ruxolitinib targets DCs: for better or worse?. Blood, 2013, 122, 1096-1097.	0.6	8
12	Genetics of Acute Lymphoblastic Leukemia. , 0, , .		0
13	The Synthetic Tryptanthrin Analogue Suppresses STAT3 Signaling and Induces Caspase Dependent Apoptosis via ERK Up Regulation in Human Leukemia HL-60 Cells. PLoS ONE, 2014, 9, e110411.	1.1	34
15	Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. International Journal of General Medicine, 2014, 7, 89.	0.8	53
16	Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia, 2014, 28, 417-419.	3.3	97
17	Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leukemia and Lymphoma, 2014, 55, 1968-1979.	0.6	23
18	The evolving genomic landscape of myeloproliferative neoplasms. Hematology American Society of Hematology Education Program, 2014, 2014, 287-296.	0.9	62
19	Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies. Cell Cycle, 2014, 13, 2827-2835.	1.3	24

#	ARTICLE	IF	CITATIONS
20	JAK/STAT Pathway in <i>Drosophila</i> Immunity. <i>Scandinavian Journal of Immunology</i> , 2014, 79, 377-385.	1.3	159
21	Gathering Support for Critical Mass: Interleukin 4 Receptor Signaling Requires Clustering in Endosomes. <i>Biophysical Journal</i> , 2014, 107, 2479-2480.	0.2	0
22	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. <i>British Journal of Haematology</i> , 2014, 167, 541-546.	1.2	47
23	The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: Lead optimization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1466-1471.	1.0	6
24	JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. <i>Blood</i> , 2014, 123, 1544-1551.	0.6	507
25	Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer. <i>Immunologic Research</i> , 2014, 58, 87-100.	1.3	22
26	Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy. <i>Leukemia</i> , 2014, 28, 419-422.	3.3	7
27	c-Abl Activates Janus Kinase 2 in Normal Hematopoietic Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 21463-21472.	1.6	9
28	Structure of the pseudokinase kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8025-8030.	3.3	176
29	Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 125-137.	2.7	75
30	Zhankuic acid A as a novel JAK2 inhibitor for the treatment of concanavalin A-induced hepatitis. <i>Biochemical Pharmacology</i> , 2014, 91, 217-230.	2.0	10
31	An Immune Dysregulation in MPN. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 331-339.	1.2	75
32	Uncovering the pathogenesis of large granular lymphocytic leukemia novel STAT3 and STAT5b mutations. <i>Annals of Medicine</i> , 2014, 46, 114-122.	1.5	62
33	Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells. <i>Journal of Hematology and Oncology</i> , 2014, 7, 37.	6.9	19
34	Take (STAT)5: jazzing up T-cell leukemia. <i>Blood</i> , 2014, 124, 1383-1384.	0.6	7
35	JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. <i>Blood</i> , 2014, 124, 3092-3100.	0.6	128
36	JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. <i>Blood</i> , 2014, 124, 2996-3006.	0.6	36
37	HijAKing T-ALL. <i>Blood</i> , 2014, 124, 3038-3040.	0.6	2

#	ARTICLE	IF	CITATIONS
38	STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7. <i>Cancer Cell International</i> , 2015, 15, 111.	1.8	28
39	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Translational Medicine</i> , 2015, 13, 294.	1.8	36
40	Potential Gene Interactions in the Cell Cycles of Gametes, Zygotes, Embryonic Stem Cells and the Development of Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 200.	1.3	1
41	Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. <i>Oncogene</i> , 2015, 34, 2991-2999.	2.6	10
42	Powikłania infekcyjne w nowotworach mieloproliferacyjnych w dobie terapii celowanych. <i>Acta Haematologica Polonica</i> , 2015, 46, 138-141.	0.1	0
43	Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice. <i>Leukemia</i> , 2015, 29, 2050-2061.	3.3	14
44	Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. <i>Blood</i> , 2015, 125, 3388-3392.	0.6	65
45	Clinical potential of pacritinib in the treatment of myelofibrosis. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 186-201.	1.1	13
46	Heixuedian (heix), a potential melanotic tumor suppressor gene, exhibits specific spatial and temporal expression pattern during drosophila hematopoiesis. <i>Developmental Biology</i> , 2015, 398, 218-230.	0.9	8
47	Lymphomagenesis in Hodgkin lymphoma. <i>Seminars in Cancer Biology</i> , 2015, 34, 14-21.	4.3	29
48	Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. <i>Cancers</i> , 2015, 7, 503-537.	1.7	17
49	The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. <i>British Journal of Cancer</i> , 2015, 113, 365-371.	2.9	460
50	Targeting the Inactive Conformation of JAK2 in Hematological Malignancies. <i>Cancer Cell</i> , 2015, 28, 1-2.	7.7	21
51	Genomic landscape of cutaneous T cell lymphoma. <i>Nature Genetics</i> , 2015, 47, 1011-1019.	9.4	347
52	A Positive Feedback Loop Between Prolactin and Stat5 Promotes Angiogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2015, 846, 265-280.	0.8	22
53	cDNA cloning and expression pattern analysis of protein inhibitor of activated STAT (PIAS) of the mud crab, <i>Scylla paramamosain</i> . <i>Aquaculture</i> , 2015, 444, 21-27.	1.7	7
54	ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4642-4647.	3.3	95
55	Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction. <i>Cell Communication and Signaling</i> , 2015, 13, 10.	2.7	11

#	ARTICLE	IF	CITATIONS
56	Novel therapies for myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2768-2778.	0.6	7
57	The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. <i>Nature Cell Biology</i> , 2015, 17, 665-677.	4.6	112
58	Clinical and molecular genetic characterization of myelofibrosis. <i>Current Opinion in Hematology</i> , 2015, 22, 177-183.	1.2	14
59	Effects of the I682F mutation on JAK2's activity, structure and stability. <i>International Journal of Biological Macromolecules</i> , 2015, 79, 118-125.	3.6	9
60	Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12480-12485.	3.3	81
61	Smoking as a contributing factor for development of polycythemia vera and related neoplasms. <i>Leukemia Research</i> , 2015, 39, 1137-1145.	0.4	36
62	A novel stereo bioactive metabolite isolated from an endophytic fungus induces caspase dependent apoptosis and STAT-3 inhibition in human leukemia cells. <i>European Journal of Pharmacology</i> , 2015, 765, 75-85.	1.7	18
63	During <i>Drosophila</i> disc regeneration, JAK/STAT coordinates cell proliferation with Dilp8-mediated developmental delay. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2327-36.	3.3	103
64	STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma. <i>Journal of Neuro-Oncology</i> , 2015, 124, 165-174.	1.4	14
65	Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 335-343.	1.2	20
66	STAT transcript levels in childhood acute lymphoblastic leukemia: STAT1 and STAT3 transcript correlations. <i>Leukemia Research</i> , 2015, 39, 1285-1291.	0.4	10
67	ADCY7 supports development of acute myeloid leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2015, 465, 47-52.	1.0	42
68	All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies. <i>Blood Reviews</i> , 2015, 29, 71-80.	2.8	14
70	Intersection of mTOR and STAT signaling in immunity. <i>Trends in Immunology</i> , 2015, 36, 21-29.	2.9	119
71	Calculating system integration costs of low-carbon generation technologies in future GB electricity system. , 2016, , .		4
72	Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 5461-5469.	0.8	45
73	Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons. <i>British Journal of Haematology</i> , 2016, 173, 625-636.	1.2	5
74	Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells. <i>Oncology Letters</i> , 2016, 12, 3598-3608.	0.8	24

#	ARTICLE	IF	CITATIONS
75	Breast Cancer Stem Cells. , 2016, , 133-151.		0
76	Antagonizing STAT5B dimerization with an osmium complex. Scientific Reports, 2016, 6, 36044.	1.6	16
77	The JAKâ€“STATâ€“SOCS Signaling Cascade. , 2016, , 136-152.		4
78	T-cell acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2016, 2016, 580-588.	0.9	176
79	Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells. Molecular Medicine Reports, 2016, 13, 3297-3302.	1.1	19
80	Discrimination Between Competing Model Structures of Biological Systems in the Presence of Population Heterogeneity. IEEE Life Sciences Letters, 2016, 2, 23-26.	1.2	7
81	Finding Synergy Networks From Gene Expression Data: A Fuzzy-Rule-Based Approach. IEEE Transactions on Fuzzy Systems, 2016, 24, 1488-1499.	6.5	3
82	A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms. Journal of Immunoassay and Immunochemistry, 2016, 37, 331-345.	0.5	6
83	Overexpression of JAK2: a predictor of unfavorable prognosis for nasopharyngeal carcinoma. Future Oncology, 2016, 12, 1887-1896.	1.1	12
84	microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. Oncogene, 2016, 35, 6001-6014.	2.6	28
85	Nucleotide-binding mechanisms in pseudokinases. Bioscience Reports, 2016, 36, e00282.	1.1	36
87	Liver protects metastatic prostate cancer from induced death by activating Eâ€“cadherin signaling. Hepatology, 2016, 64, 1725-1742.	3.6	32
88	Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population. Frontiers of Medicine, 2016, 10, 437-443.	1.5	2
89	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood, 2016, 127, 1325-1335.	0.6	261
90	Involvement of transcription factor Oct-1 in the regulation of JAKâ€“STAT signaling pathway in cells of Burkitt lymphoma. Doklady Biochemistry and Biophysics, 2016, 468, 229-231.	0.3	2
91	The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nature Reviews Cancer, 2016, 16, 494-507.	12.8	348
92	Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling. Science Signaling, 2016, 9, ra109.	1.6	80
93	Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 1-25.	0.1	0

#	ARTICLE	IF	CITATIONS
94	Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization. <i>Scientific Reports</i> , 2016, 6, 35454.	1.6	11
95	Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and Nontargeted Mediators after siRNA Treatment. <i>Molecular Pharmaceutics</i> , 2016, 13, 4116-4128.	2.3	17
96	Cytokine-induced megakaryocytic differentiation is regulated by genome-wide loss of a <sc>uSTAT</sc> transcriptional program. <i>EMBO Journal</i> , 2016, 35, 580-594.	3.5	66
97	Apontic regulates somatic stem cell numbers in <i>Drosophila</i> testes. <i>BMC Developmental Biology</i> , 2016, 16, 5.	2.1	12
98	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90 Kinase Interactions. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5563-5586.	2.9	53
99	TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies. <i>Cytokine</i> , 2016, 82, 52-57.	1.4	58
100	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. <i>Leukemia Research</i> , 2016, 41, 36-42.	0.4	41
101	Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma and Lymphoma, 2016, 57, 899-908.	0.6	7
102	Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. <i>Leukemia</i> , 2016, 30, 94-103.	3.3	27
103	RNA interference for multiple myeloma therapy: targeting signal transduction pathways. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 107-121.	1.5	16
104	New insights of common gamma chain in hematological malignancies. <i>Cytokine</i> , 2017, 89, 179-184.	1.4	6
105	Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. <i>Cytokine</i> , 2017, 89, 209-218.	1.4	45
106	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. <i>Leukemia</i> , 2017, 31, 83-91.	3.3	87
107	Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 391-398.	0.6	7
108	Pseudokinases: update on their functions and evaluation as new drug targets. <i>Future Medicinal Chemistry</i> , 2017, 9, 245-265.	1.1	71
109	Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. <i>Leukemia</i> , 2017, 31, 2122-2131.	3.3	27
110	Paroxysmal Nocturnal Hemoglobinuria. , 2017, , .		1
111	Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition. <i>Leukemia</i> , 2017, 31, 1023-1038.	3.3	51

#	ARTICLE	IF	CITATIONS
112	CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling. <i>Oncogene</i> , 2017, 36, 3695-3705.	2.6	25
113	Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. <i>Annual Review of Immunology</i> , 2017, 35, 533-550.	9.5	139
114	Regulation of Hematopoiesis and Hematological Disease by TGF- β Family Signaling Molecules. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a027987.	2.3	25
115	The secret life of kinases: insights into non-catalytic signalling functions from pseudokinases. <i>Biochemical Society Transactions</i> , 2017, 45, 665-681.	1.6	71
116	JAK1 somatic mutation in a myeloproliferative neoplasm. <i>Haematologica</i> , 2017, 102, e324-e327.	1.7	9
117	Proliferation Drives Aging-Related Functional Decline in a Subpopulation of the Hematopoietic Stem Cell Compartment. <i>Cell Reports</i> , 2017, 19, 1503-1511.	2.9	76
118	Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. <i>British Journal of Cancer</i> , 2017, 117, 256-265.	2.9	34
119	Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 1-14.	1.6	228
120	Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1095-1101.	2.0	89
121	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. <i>Blood</i> , 2017, 129, 667-679.	0.6	444
122	T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw248.	3.0	28
123	Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. <i>Biomedical Reports</i> , 2017, 7, 370-376.	0.9	10
124	JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation. <i>Journal of Veterinary Internal Medicine</i> , 2017, 31, 1804-1815.	0.6	14
125	TC-PTP regulates the IL-7 transcriptional response during murine early T cell development. <i>Scientific Reports</i> , 2017, 7, 13275.	1.6	9
126	High expression of CPNE 3 predicts adverse prognosis in acute myeloid leukemia. <i>Cancer Science</i> , 2017, 108, 1850-1857.	1.7	14
127	Twenty five years of Cytokine: on a forward path to exciting discoveries of pathological mechanisms and therapeutics. <i>Cytokine</i> , 2017, 98, 1-3.	1.4	3
128	Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors. <i>Trends in Cancer</i> , 2017, 3, 816-827.	3.8	53
129	Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. <i>EBioMedicine</i> , 2017, 26, 112-125.	2.7	35

#	ARTICLE	IF	CITATIONS
130	p.Y317H is a new <i>JAK2</i> gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with <i>CALR</i> mutation. <i>Haematologica</i> , 2017, 102, e328-e331.	1.7	6
131	Artesunate induces apoptosis via inhibition of STAT3 in THP-1 cells. <i>Leukemia Research</i> , 2017, 62, 98-103.	0.4	23
132	The promise of Janus kinase inhibitors in the treatment of hematological malignancies. <i>Cytokine</i> , 2017, 98, 33-41.	1.4	35
133	Loss of p300 accelerates MDS-associated leukemogenesis. <i>Leukemia</i> , 2017, 31, 1382-1390.	3.3	34
134	Advances in Pathobiology of Primary Central Nervous System Lymphoma. <i>Chinese Medical Journal</i> , 2017, 130, 1973-1979.	0.9	15
135	Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways. <i>Blood Advances</i> , 2017, 1, 1749-1759.	2.5	19
136	Cytokine Signaling in Tumor Progression. <i>Immune Network</i> , 2017, 17, 214.	1.6	62
137	The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin. <i>Frontiers in Endocrinology</i> , 2017, 8, 59.	1.5	56
138	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in <i>JAK2</i> and <i>JAK3</i> with therapeutic implications. <i>Genome Medicine</i> , 2017, 9, 89.	3.6	39
139	Genomics of Myeloproliferative Neoplasms. <i>Journal of Clinical Oncology</i> , 2017, 35, 947-954.	0.8	62
140	Prognostic relevance of protein expression, clinical factors, and <i>MYD88</i> mutation in primary bone lymphoma. <i>Oncotarget</i> , 2017, 8, 65609-65619.	0.8	8
141	Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. <i>Oncologist</i> , 2018, 23, 1039-1053.	1.9	41
142	<i>C. elegans</i> -based screen identifies lysosome-damaging alkaloids that induce STAT3-dependent lysosomal cell death. <i>Protein and Cell</i> , 2018, 9, 1013-1026.	4.8	14
143	HSP27 is a partner of <i>JAK2</i> -STAT5 and a potential therapeutic target in myelofibrosis. <i>Nature Communications</i> , 2018, 9, 1431.	5.8	21
144	Pathogenesis of Peripheral T Cell Lymphoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 293-320.	9.6	36
145	Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-V β 2+ expansions. <i>Scientific Reports</i> , 2018, 8, 2534.	1.6	2
146	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1135-1146.	3.3	112
147	Melanoma response to anti-PD-L1 immunotherapy requires <i>JAK1</i> signaling, but not <i>JAK2</i> . <i>Oncolmmunology</i> , 2018, 7, e1438106.	2.1	54

#	ARTICLE	IF	CITATIONS
148	<i><sc>STAT</sc>3</i> mutations are not sufficient to induce large granular lymphocytic leukaemia in mice. <i>British Journal of Haematology</i> , 2018, 180, 911-915.	1.2	16
149	The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. <i>Leukemia</i> , 2018, 32, 809-819.	3.3	57
150	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical researchâ€practice gaps, challenges, and insights. <i>Medicinal Research Reviews</i> , 2018, 38, 325-376.	5.0	50
151	Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Nonâ€Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling. <i>Clinical Cancer Research</i> , 2018, 24, 1227-1239.	3.2	51
152	Cucurbitacin I inhibits STAT3, but enhances STAT1 signaling in human cancer cells in vitro through disrupting actin filaments. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 425-437.	2.8	31
153	pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 147-152.	0.6	7
154	Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation. <i>ELife</i> , 2018, 7, .	2.8	46
156	The regulatory role of the kinase-homology domain in receptor guanylyl cyclases: nothing â€pseudoâ€™ about it!. <i>Biochemical Society Transactions</i> , 2018, 46, 1729-1742.	1.6	8
157	Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain. <i>Frontiers in Oncology</i> , 2018, 8, 560.	1.3	13
158	A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions. <i>Frontiers in Pharmacology</i> , 2018, 9, 1379.	1.6	26
159	Future potential of osmium complexes as anticancer drug candidates, photosensitizers and organelle-targeted probes. <i>Dalton Transactions</i> , 2018, 47, 14841-14854.	1.6	74
160	JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. <i>F1000Research</i> , 2018, 7, 82.	0.8	126
161	STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. <i>Cell Reports</i> , 2018, 24, 3045-3060.e5.	2.9	20
162	Type 2 diabetes â€An autoinflammatory disease driven by metabolic stress. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3805-3823.	1.8	60
163	Comparative Analysis of TCSC and STATCOM in Power System. , 2018, , .		2
164	Asymptotic Properties of a Cheap Control Infinite Horizon Nash Differential Game. , 2018, , .		0
165	Coverage Algorithm for Covering Maximal Area within Deadline. , 2018, , .		0
166	Force Sensor Clamp for Fixation of Ultra-thin Membrane Using Micro-hole Array for Tensile Characterization*. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
168	A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability. <i>Journal of Cell Science</i> , 2018, 131, .	1.2	18
170	Molecular Mechanisms of Gastrointestinal Signaling. , 2018, , 227-315.		0
171	Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. <i>PLoS ONE</i> , 2018, 13, e0199108.	1.1	39
172	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6056-6074.	2.9	84
173	Multi-OMICS analyses unveil <i>STAT1</i> as a potential modifier gene in mevalonate kinase deficiency. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1675-1687.	0.5	19
174	New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update. <i>Cancers</i> , 2018, 10, 110.	1.7	35
175	Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase. <i>Frontiers in Endocrinology</i> , 2017, 8, 361.	1.5	69
176	The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects. <i>Frontiers in Endocrinology</i> , 2018, 9, 35.	1.5	188
177	The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. <i>Cancers</i> , 2018, 10, 104.	1.7	81
178	CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia. <i>Cell Death and Disease</i> , 2018, 9, 774.	2.7	17
179	Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species. <i>European Journal of Pharmacology</i> , 2018, 834, 65-76.	1.7	26
180	Chromosomal Instability in Hodgkin Lymphoma: An In-Depth Review and Perspectives. <i>Cancers</i> , 2018, 10, 91.	1.7	29
181	Role of Non Receptor Tyrosine Kinases in Hematological Malignancies and its Targeting by Natural Products. <i>Molecular Cancer</i> , 2018, 17, 31.	7.9	79
182	Oxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2/STAT3 pathway. <i>International Journal of Immunopathology and Pharmacology</i> , 2018, 32, 205873841878163.	1.0	27
183	Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium. <i>Dalton Transactions</i> , 2018, 47, 9934-9974.	1.6	207
184	The regulation of JAKs in cytokine signaling and its breakdown in disease. <i>Cytokine</i> , 2019, 118, 48-63.	1.4	145
185	Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study. <i>BMC Veterinary Research</i> , 2019, 15, 291.	0.7	3
186	Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. <i>PLoS ONE</i> , 2019, 14, e0220189.	1.1	3

#	ARTICLE	IF	CITATIONS
187	Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells. <i>International Journal of Biological Macromolecules</i> , 2019, 137, 1030-1040.	3.6	8
188	Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 749-757.	1.1	16
189	Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects. <i>Drugs</i> , 2019, 79, 1499-1509.	4.9	24
190	Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer. <i>Current Medicinal Chemistry</i> , 2019, 26, 973-987.	1.2	19
191	TYK2: An Upstream Kinase of STATs in Cancer. <i>Cancers</i> , 2019, 11, 1728.	1.7	41
192	STAT5A and STAT5B "Twins with Different Personalities in Hematopoiesis and Leukemia. <i>Cancers</i> , 2019, 11, 1726.	1.7	38
193	STAT3 Dysregulation in Mature T and NK Cell Lymphomas. <i>Cancers</i> , 2019, 11, 1711.	1.7	23
194	Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10305-10320.	2.9	24
195	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. <i>BMC Cancer</i> , 2019, 19, 1080.	1.1	17
196	Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models. <i>Scientific Reports</i> , 2019, 9, 16379.	1.6	6
197	Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent. <i>Cells</i> , 2019, 8, 898.	1.8	95
198	Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 891-898.	1.1	21
199	Down-regulated microRNA-183 mediates the Jak/Stat signaling pathway to attenuate hippocampal neuron injury in epilepsy rats by targeting Foxp1. <i>Cell Cycle</i> , 2019, 18, 3206-3222.	1.3	17
200	Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia. <i>International Journal of Biological Macromolecules</i> , 2019, 136, 209-219.	3.6	6
201	The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. <i>Expert Review of Hematology</i> , 2019, 12, 437-448.	1.0	20
202	Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal Cancer. <i>Cancers</i> , 2019, 11, 669.	1.7	7
203	Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage. <i>European Journal of Pharmacology</i> , 2019, 855, 252-261.	1.7	13
204	Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108913.	2.5	12

#	ARTICLE	IF	CITATIONS
205	The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Therapeutic Advances in Hematology, 2019, 10, 204062071984159.	1.1	23
206	The inhibition of miR-126 in cell migration and invasion of cervical cancer through regulating ZEB1. Hereditas, 2019, 156, 11.	0.5	30
207	The expression of miR-375 in prostate cancer: A study based on GEO, TCGA data and bioinformatics analysis. Pathology Research and Practice, 2019, 215, 152375.	1.0	25
208	Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor. Oncology Letters, 2019, 17, 3981-3989.	0.8	41
209	Investigation of Empirical and Semi-Empirical Charges to Study the Effects of Partial Charges on Quality and Prediction Accuracy in 3D-QSAR. ChemistrySelect, 2019, 4, 3990-4002.	0.7	2
210	Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respiratory Medicine: X, 2019, 1, 100004.	1.4	25
211	Origins and clinical relevance of proteoforms in pediatric malignancies. Expert Review of Proteomics, 2019, 16, 185-200.	1.3	12
212	The Yin-Yang of cytokines in cancer. Cytokine, 2019, 118, 1-2.	1.4	6
213	Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold. Bioorganic and Medicinal Chemistry, 2019, 27, 1562-1576.	1.4	17
214	Runx1 promotes the development of glioma cells by regulating JAK-STAT signalling pathway. Archives of Medical Science, 2019, 18, 761-776.	0.4	2
215	PhishFry - A Proactive Approach to Classify Phishing Sites Using SCIKIT Learn. , 2019, , .		3
216	MPPT Based Adaptive Control Algorithm for Small Scale Wind Energy Conversion Systems with PMSG. , 2019, , .		1
217	Scaling of Components for Explicit Modelling of Heat Transfer during Vapour Phase Reflow Soldering. , 2019, , .		0
218	Material Parameter Extraction in THz Domain, Simplifications and Sensitivity Analysis. , 2019, , .		1
219	Herding an Adversarial Swarm in an Obstacle Environment. , 2019, , .		10
221	Ad Blocking Whitelist Prediction for Online Publishers. , 2019, , .		2
222	Web Service Clustering on the Basis of QoS Parameters. , 2019, , .		2
224	IWBIS 2019 Program Schedule. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
227	Collaborative Object Transportation by Multiple Robots with Onboard Object Localization Algorithm. , 2019, , .		3
228	Coordinated Control of an Ultracapacitor Bank and a Variable-Speed Wind Turbine Generator for Inertial Response Provision During Low and Above Rated Wind Speeds. , 2019, , .		3
229	Advances in the prevention and monitoring of root dentin demineralization using lasers. , 2019, , .		2
230	ComSDS 2019 Cover Page. , 2019, , .		0
231	Gait Recognition from Markerless 3D Motion Capture. , 2019, , .		2
232	Algorithm for Mining Network-Constrained Movement Patterns between Zones from Spatiotemporal OD Flows. , 2019, , .		2
233	Measurement-based Optimal Power Flow with Linear Power-flow Constraint for DER Dispatch. , 2019, , .		2
234	Optimal Design Methodology for High-Power Interleaved Bidirectional Buck-Boost Converters for Supercapacitors in Vehicular Applications. , 2019, , .		0
235	Audio classification systems using deep neural networks and an event-driven auditory sensor. , 2019, , .		3
236	A Device for Measuring of Frequency Response Function of Biopotentials. , 2019, , .		8
237	Extending the Lifetime of Coarse-Grained Runtime Reconfigurable FPGAs by Balancing Processing Element Usage. , 2019, , .		0
238	Boosting E-Service Quality through IT Service Management of Online Stores. , 2019, , .		1
239	JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors. HemaSphere, 2019, 3, e313.	1.2	12
240	Non-receptor Tyrosine Kinases Role and Significance in Hematological Malignancies. , 2019, , .		9
241	Activating mutations of the gp130/JAK/STAT pathway in human diseases. Advances in Protein Chemistry and Structural Biology, 2019, 116, 283-309.	1.0	24
242	Understanding the structural features of JAK2 inhibitors: a combined 3D-QSAR, DFT and molecular dynamics study. Molecular Diversity, 2019, 23, 845-874.	2.1	11
243	Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. Leukemia and Lymphoma, 2019, 60, 821-824.	0.6	2
244	Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia. International Journal of Biological Macromolecules, 2019, 124, 1123-1131.	3.6	7

#	ARTICLE	IF	CITATIONS
245	The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1193-1203.	0.6	13
246	Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms. <i>Investigational New Drugs</i> , 2020, 38, 610-620.	1.2	5
248	Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling. <i>Cancers</i> , 2020, 12, 78.	1.7	22
249	Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. <i>Modern Pathology</i> , 2020, 33, 1092-1103.	2.9	18
250	A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies. <i>Acta Biomaterialia</i> , 2020, 102, 351-366.	4.1	17
251	<p>Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 7901-7921.	3.3	22
252	Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12403-12428.	2.9	48
253	Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 671-684.	0.7	7
254	Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. <i>Haematologica</i> , 2020, 106, haematol.2020.249441.	1.7	2
255	Chemokine-like factor 1: A promising therapeutic target in human diseases. <i>Experimental Biology and Medicine</i> , 2020, 245, 1518-1528.	1.1	15
256	Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2020, 9, 2934.	1.0	57
257	Molecular Pathogenesis of Hodgkin Lymphoma: Past, Present, Future. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6623.	1.8	11
258	Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 2250.	1.7	10
259	ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma. <i>Cell Death and Disease</i> , 2020, 11, 337.	2.7	21
260	A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 42, 100712.	2.8	16
261	A cytokine receptor domeless promotes white spot syndrome virus infection via JAK/STAT signaling pathway in red claw crayfish <i>Cherax quadricarinatus</i> . <i>Developmental and Comparative Immunology</i> , 2020, 111, 103749.	1.0	7
262	Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 87-95.	1.1	9
263	STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK ⁺ ALCL. <i>Cancers</i> , 2020, 12, 702.	1.7	17

#	ARTICLE	IF	CITATIONS
264	Experimental Study on the Short-Circuit Instability of Cascode GaN HEMTs. IEEE Transactions on Electron Devices, 2020, 67, 1686-1692.	1.6	14
265	Semantic Segmentation of LiDAR Points Clouds: Rasterization Beyond Digital Elevation Models. IEEE Geoscience and Remote Sensing Letters, 2020, 17, 2016-2019.	1.4	11
266	Sex disparities in head & neck cancer driver genes: An analysis of the TCGA dataset. Oral Oncology, 2020, 104, 104614.	0.8	21
267	Impact of Feature Selection on Non-technical Loss Detection. , 2020, , .		6
268	Investigational non-JAK inhibitors for chronic phase myelofibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 461-474.	1.9	13
269	Apixaban exhibits anti-arthritis effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways. Inflammopharmacology, 2020, 28, 1253-1267.	1.9	14
270	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers, 2020, 12, 1763.	1.7	17
271	Targeting nuclear import and export in hematological malignancies. Leukemia, 2020, 34, 2875-2886.	3.3	40
272	Immune-modulating and anti-inflammatory marine compounds against cancer. Seminars in Cancer Biology, 2022, 80, 58-72.	4.3	24
273	The Role of JAK-STAT Signaling Activation in Hypertrophied Ligamentum Flavum. World Neurosurgery, 2020, 137, e506-e516.	0.7	5
274	A Novel Image Encryption Algorithm Based on Parameter-Control Scroll Chaotic Attractors. IEEE Access, 2020, 8, 36281-36292.	2.6	9
275	An Exact Method and Ant Colony Optimization for Single Machine Scheduling Problem With Time Window Periodic Maintenance. IEEE Access, 2020, 8, 44836-44845.	2.6	7
276	Whole Genome Sequencing of Spontaneously Occurring Rat Natural Killer Large Granular Lymphocyte Leukemia Identifies JAK1 Somatic Activating Mutation. Cancers, 2020, 12, 126.	1.7	2
277	Steamed Panax notoginseng Attenuates Anemia in Mice With Blood Deficiency Syndrome via Regulating Hematopoietic Factors and JAK-STAT Pathway. Frontiers in Pharmacology, 2019, 10, 1578.	1.6	30
278	Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. Science, 2020, 367, 643-652.	6.0	123
279	Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers, 2020, 12, 240.	1.7	49
280	Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. Cancer Chemotherapy and Pharmacology, 2020, 85, 899-906.	1.1	13
281	Mining database for the expression and gene regulation network of JAK2 in skin cutaneous melanoma. Life Sciences, 2020, 253, 117600.	2.0	5

#	ARTICLE	IF	CITATIONS
282	Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. <i>Pharmacological Reviews</i> , 2020, 72, 486-526.	7.1	174
283	6.2 A 460mW 112Gb/s DSP-Based Transceiver with 38dB Loss Compensation for Next-Generation Data Centers in 7nm FinFET Technology. , 2020, , .		44
284	<p>Long Noncoding RNA SOCS2-AS Promotes Leukemogenesis in FLT3-ITD+ Acute Myeloid Leukemia Through miRNA-221</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2925-2934.	1.0	6
285	Decentralized Local Energy Trading in Microgrids With Voltage Management. <i>IEEE Transactions on Industrial Informatics</i> , 2021, 17, 1111-1121.	7.2	41
286	The Association of Pre-diagnostic Inflammatory Markers and Adipokines and the Risk of Non-Hodgkin Lymphoma Development in Egypt. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 76-81.	0.3	1
287	Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. <i>Blood</i> , 2021, 137, 2347-2359.	0.6	31
288	MiRNAs directly targeting the key intermediates of biological pathways in pancreatic cancer. <i>Biochemical Pharmacology</i> , 2021, 189, 114357.	2.0	11
289	The role of selenium in cell survival and its correlation with protective effects against cardiovascular disease: A literature review. <i>Biomedicine and Pharmacotherapy</i> , 2021, 134, 111125.	2.5	24
290	High Expression of Interleukin-2 Receptor Subunit Gamma Reveals Poor Prognosis in Human Gastric Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	2
291	Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms. <i>Oncology Letters</i> , 2021, 21, 204.	0.8	3
292	Polyphenols Targeting and Influencing Cellular Signaling During Progression and Treatment of Cancer. , 2021, , 95-141.		0
294	Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II. <i>American Journal of Surgical Pathology</i> , 2021, 45, 905-916.	2.1	24
295	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1906.	1.8	19
296	JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 865-875.	0.5	123
297	Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. <i>Autoimmunity Reviews</i> , 2021, 20, 102750.	2.5	36
298	Targeting Protein Kinases in Blood Cancer: Focusing on CK1 β and CK2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3716.	1.8	18
299	Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies. <i>Pharmaceuticals</i> , 2021, 14, 443.	1.7	13
300	Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitorsâ€”A Strategy for Hematological Malignancies?. <i>Cancers</i> , 2021, 13, 2611.	1.7	15

#	ARTICLE	IF	CITATIONS
301	Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 369-377.	1.1	5
302	PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 97.	6.9	10
303	Functional Consequences of Mutations in Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021, 5, e578.	1.2	22
304	Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective. <i>Computers in Biology and Medicine</i> , 2021, 134, 104406.	3.9	14
305	Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7576.	1.8	5
306	miR-383 reduces keratinocyte proliferation and induces the apoptosis in psoriasis via disruption of LCN2-dependent JAK/STAT pathway activation. <i>International Immunopharmacology</i> , 2021, 96, 107587.	1.7	17
307	T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness. <i>Genes</i> , 2021, 12, 1118.	1.0	35
308	Bleeding diathesis in mice lacking JAK2 in platelets. <i>Blood Advances</i> , 2021, 5, 2969-2981.	2.5	7
309	In and out: Traffic and dynamics of thrombopoietin receptor. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9073-9083.	1.6	3
310	Alterations of Signaling Pathways in Essential Thrombocythemia with Calreticulin Mutation. <i>Cancer Management and Research</i> , 2021, Volume 13, 6231-6238.	0.9	5
311	TYK2 in Cancer Metastases: Genomic and Proteomic Discovery. <i>Cancers</i> , 2021, 13, 4171.	1.7	14
312	Potential role of melatonin in prevention and treatment of leukaemia. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2021, 42, 445-461.	0.3	2
313	The Emerging Role of Suppressors of Cytokine Signaling (SOCS) in the Development and Progression of Leukemia. <i>Cancers</i> , 2021, 13, 4000.	1.7	14
314	PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. <i>Leukemia</i> , 2022, 36, 370-382.	3.3	18
315	PD-1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients. <i>Journal of Pathology: Clinical Research</i> , 2021, , .	1.3	2
316	SOCS Proteins in Immunity, Inflammatory Diseases, and Immune-Related Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 727987.	1.2	58
317	The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYC signaling axis. <i>Cell Death Discovery</i> , 2021, 7, 268.	2.0	4
318	Role of Janus Kinase Inhibitors in Therapy of Psoriasis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4307.	1.0	25

#	ARTICLE	IF	CITATIONS
319	Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 941-952.	1.1	10
320	Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential. <i>Biochemical Pharmacology</i> , 2021, 193, 114760.	2.0	42
321	Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113768.	2.6	52
322	Accelerating <i>De Novo</i> Drug Design against Novel Proteins Using Deep Learning. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 621-630.	2.5	55
323	Increased risk of leukaemia in children with Down syndrome: a somatic evolutionary view. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e5.	1.6	3
324	Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia. <i>Cancers</i> , 2021, 13, 184.	1.7	40
325	Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells. <i>Archives of Medical Science</i> , 2021, 17, 266-274.	0.4	6
326	Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia. <i>Anticancer Research</i> , 2021, 41, 731-737.	0.5	3
327	Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 561.	1.8	20
328	The PTP1B mutant PTP1B ^{Δ24} is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma. <i>Carcinogenesis</i> , 2021, 42, 517-527.	1.3	11
329	Rare mutations provide unique insight into oncogenic potential of STAT transcription factors. <i>Journal of Clinical Investigation</i> , 2017, 128, 113-115.	3.9	5
330	Mutational Spectrum Of Adult T-ALL. <i>Blood</i> , 2013, 122, 828-828.	0.6	2
331	Leucine-Rich Alpha-2-Glycoprotein1 Gene Interferes with Regulation of Apoptosis in Leukemia KASUMI-1 Cells. <i>Medical Science Monitor</i> , 2018, 24, 8348-8356.	0.5	15
332	Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway. <i>PLoS ONE</i> , 2015, 10, e0135463.	1.1	36
333	Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. <i>PLoS ONE</i> , 2017, 12, e0174835.	1.1	31
334	Transcriptomic Profiles of MV4-11 and Kasumi 1 Acute Myeloid Leukemia Cell Lines Modulated by Epigenetic Modifiers Trichostatin A and 5-Azacytidine. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 0, , .	0.3	2
335	Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. <i>Oncotarget</i> , 2016, 7, 76793-76805.	0.8	32
336	Mutational spectrum of adult T-ALL. <i>Oncotarget</i> , 2015, 6, 2754-2766.	0.8	98

#	ARTICLE	IF	CITATIONS
337	Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. <i>Oncotarget</i> , 2014, 5, 6788-6800.	0.8	32
338	Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma. <i>Oncotarget</i> , 2018, 9, 14338-14353.	0.8	12
339	Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 44703-44713.	0.8	21
340	Targeting the JAK/STAT pathway in solid tumors. <i>Journal of Cancer Metastasis and Treatment</i> , 0, 2020, .	0.5	46
341	Targeting Immune Signaling Pathways in Clonal Hematopoiesis. <i>Current Medicinal Chemistry</i> , 2019, 26, 5262-5277.	1.2	6
342	Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets. <i>Current Pharmaceutical Design</i> , 2015, 21, 1227-1238.	0.9	23
343	STAT3: A Potential Drug Target for Tumor and Inflammation. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1305-1317.	1.0	48
344	The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases. <i>Ecancermedicalsecience</i> , 2020, 14, 1011.	0.6	3
345	Drosophila as a model to study the role of blood cells in inflammation, innate immunity and cancer. <i>Frontiers in Cellular and Infection Microbiology</i> , 2014, 3, 113.	1.8	76
346	The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice. <i>Molecular Medicine Reports</i> , 2019, 20, 4883-4892.	1.1	17
347	A Recurrent STAT5B N642H Driver Mutation in Feline Alimentary T Cell Lymphoma. <i>Cancers</i> , 2021, 13, 5238.	1.7	4
348	PLC β 1/PKC δ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1391-1400.e15.	0.3	5
349	Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, , .	1.2	2
350	A systematic analysis of genetic interactions and their underlying biology in childhood cancer. <i>Communications Biology</i> , 2021, 4, 1139.	2.0	2
351	Pathogenesis of Clonal Dominance in PNH: Growth Advantage in PNH. , 2017, , 229-251.		0
353	Updates in Polycythemia Vera. <i>Molecular Pathology Library</i> , 2018, , 115-139.	0.1	0
355	Transcriptome Changes in Colorectal Cancer Cells upon Treatment with Avicquinone B. <i>Advanced Pharmaceutical Bulletin</i> , 2020, 10, 638-647.	0.6	3
356	Myelofibrozis hastalarında Ruxolitinib kullanımı: tek merkez deneyimi ve JAK-2 allel y $\frac{1}{4}$ k $\frac{1}{4}$ ile Ruxolitinib yanıtı arasındaki ilişki. <i>Pamukkale Medical Journal</i> , 0, , .	0.2	0

#	ARTICLE	IF	CITATIONS
357	JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy. <i>Cancer Biology and Therapy</i> , 2021, 22, 66-78.	1.5	1
358	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. <i>Haematologica</i> , 2022, 107, 201-210.	1.7	12
359	The JAK2 mutation. <i>International Review of Cell and Molecular Biology</i> , 2021, 365, 117-162.	1.6	4
360	The Effects of Tofacitinib-Mediated Janus Kinase/Signal Transducers and Activators of the Transcription Signal Pathway Inhibition on Collagen Biosynthesis in Hepatic and Skin Fibroblast Cell Culture. <i>Archives of Rheumatology</i> , 2020, 35, 343-350.	0.3	1
363	Phloridzin docosahexaenoate, a novel flavonoid derivative, suppresses growth and induces apoptosis in T-cell acute lymphoblastic leukemia cells. <i>American Journal of Cancer Research</i> , 2017, 7, 2452-2464.	1.4	3
364	Transcriptomic Profiles of MV4-11 and Kasumi 1 Acute Myeloid Leukemia Cell Lines Modulated by Epigenetic Modifiers Trichostatin A and 5-Azacytidine. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2020, 14, 72-92.	0.3	3
366	Targeting the JAK/STAT pathway in solid tumors. <i>Journal of Cancer Metastasis and Treatment</i> , 2020, 6, .	0.5	21
367	STAT5 inhibitor Pimozide as a probable therapeutic option in overcoming Ponatinib resistance in K562 leukemic cells. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 186-199.	2.0	1
368	Janus Kinase. , 2021, , 893-902.		0
369	Oncogenic TYK2 ^{P760L} kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade. <i>Haematologica</i> , 2022, , .	1.7	1
370	Protein Tyrosine Phosphatase 1B (PTP1B): Insights into its New Implications in Tumorigenesis. <i>Current Cancer Drug Targets</i> , 2022, 22, 181-194.	0.8	3
371	Proteomimetics of Natural Regulators of JAK-STAT Pathway: Novel Therapeutic Perspectives. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 792546.	1.6	8
373	Cytokine Receptors-Regulators of Antimycobacterial Immune Response. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1112.	1.8	7
374	Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia. <i>Cancer Gene Therapy</i> , 2022, 29, 1140-1152.	2.2	4
375	Pathogenic signaling in multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 27-40.	0.8	6
376	Exploring the Associations Between Clonal Hematopoiesis of Indeterminate Potential, Myeloid Malignancy, and Atherosclerosis. <i>Methods in Molecular Biology</i> , 2022, 2419, 73-88.	0.4	3
377	JAK2-Mediated Phosphorylation of Stress-Induced Phosphoprotein-1 (STIP1) in Human Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2420.	1.8	7
378	Blood-Enriching Effects and Immune-Regulation Mechanism of Steam-Processed Polygonatum Sibiricum Polysaccharide in Blood Deficiency Syndrome Mice. <i>Frontiers in Immunology</i> , 2022, 13, 813676.	2.2	7

#	ARTICLE	IF	CITATIONS
379	Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2022, 12, 37.	2.8	4
380	CYT387, a JAK-Specific Inhibitor Impedes Osteoclast Activity and Oophorectomy-Induced Osteoporosis via Modulating RANKL and ROS Signaling Pathways. <i>Frontiers in Pharmacology</i> , 2022, 13, 829862.	1.6	7
381	A concise review on tyrosine kinase targeted cancer therapy. <i>Current Drug Therapy</i> , 2022, 17, .	0.2	1
382	Genetic Landscape of Peripheral T-Cell Lymphoma. <i>Life</i> , 2022, 12, 410.	1.1	8
383	Novel Compound, ND-17, Regulates the JAK/STAT, PI3K/AKT, and MAPK Pathways and Restrains Human T-Lymphoid Leukemia Development. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	2
384	Copy number gain of <i>JAK2</i> on marker chromosome in a case of relapsed pediatric B-ALL. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29658.	0.8	2
385	Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 64, 128680.	1.0	6
386	O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia. <i>Phytomedicine</i> , 2022, 100, 154061.	2.3	5
387	Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. <i>Cancer Research</i> , 2022, 82, 749-763.	0.4	20
388	Upadacitinib as Novel Treatment for Rheumatoid Arthritis with T-Cell Granular Lymphocytic Leukemia: A Case Report and Narrative Review. <i>Journal of Clinical Rheumatology and Immunology</i> , 2022, 22, 22-30.	0.4	2
389	MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers. <i>Genes and Diseases</i> , 2022, 9, 849-867.	1.5	13
390	Global expression profiling of CD10 ⁺ /CD19 ⁺ pre-B lymphoblasts from Hispanic B-ALL patients correlates with comparative TARGET database analysis. <i>Discover Oncology</i> , 2022, 13, 28.	0.8	0
395	Targeting SHP2 phosphatase in hematological malignancies. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 319-332.	1.5	10
396	Platelet Versus Megakaryocyte: Who Is the Real Bandleader of Thromboinflammation in Sepsis?. <i>Cells</i> , 2022, 11, 1507.	1.8	8
397	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. <i>British Journal of Haematology</i> , 2022, 198, 317-327.	1.2	18
398	Targeted Next-generation Sequencing Reveals a Wide Morphologic and Immunophenotypic Spectrum of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1207-1218.	2.1	7
399	Adipose tissue-derived mesenchymal stem cells' acellular product extracellular vesicles as a potential therapy for Crohn's disease. <i>Journal of Cellular Physiology</i> , 2022, , .	2.0	6
400	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. <i>Leukemia</i> , 2022, 36, 1759-1768.	3.3	4

#	ARTICLE	IF	CITATIONS
401	Quercetin encapsulated in folic acid-modified liposomes is therapeutic against osteosarcoma by non-covalent binding to the JH2 domain of JAK2 Via the JAK2-STAT3-PDL1. <i>Pharmacological Research</i> , 2022, 182, 106287.	3.1	20
402	Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
403	Biochemical, Enzymatic, and Computational Characterization of Recurrent Somatic Mutations of the Human Protein Tyrosine Phosphatase PTP1B in Primary Mediastinal B Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7060.	1.8	3
404	LINC00893 inhibits the progression of prostate cancer through miR-3173-5p/SOCS3/JAK2/STAT3 pathway. <i>Cancer Cell International</i> , 2022, 22, .	1.8	9
405	JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	11
406	Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
407	Multimomics to investigate the mechanisms contributing to repression of <i>PTPRC</i> and <i>SOCS2</i> in pediatric ALL: Focus on miR-3633 and promoter methylation. <i>Genes Chromosomes and Cancer</i> , 0, , .	1.5	1
408	Discovery of Hexahydrofuro[3,2- <i>b</i>]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 10674-10690.	2.9	4
409	Evaluating the Role of Cytokine Receptor-like Factor 2 and Janus Kinase 2 in Adult Acute Lymphoblastic Leukemia. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 1622-1631.	0.1	0
410	Comprehensive view on genetic features, therapeutic modalities and prognostic models in adult T-cell lymphoblastic lymphoma. <i>Blood Science</i> , 2022, 4, 155-160.	0.4	1
411	Germline Variants Associated with Nasopharyngeal Carcinoma Predisposition Identified through Whole-Exome Sequencing. <i>Cancers</i> , 2022, 14, 3680.	1.7	1
412	miR-29b-3p suppresses the malignant biological behaviors of AML cells via inhibiting NF- κ B and JAK/STAT signaling pathways by targeting HuR. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
413	Molecular Pathogenesis of Hodgkin's Lymphoma: Advances Through the Key Player LMP1 and 3D Nanotechnology. , 2022, , .		0
414	Endocytosis of the thrombopoietin receptor Mpl regulates megakaryocyte and erythroid maturation in mice. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
415	Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations. <i>Investigational New Drugs</i> , 0, , .	1.2	0
416	Life at the periphery: what makes CHO cells survival talents. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 6157-6167.	1.7	2
417	Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1 mouse model. <i>Experimental Hematology</i> , 2023, 117, 43-61.	0.2	3
418	Advanced approaches of developing targeted covalent drugs. <i>RSC Medicinal Chemistry</i> , 2022, 13, 1460-1475.	1.7	7

#	ARTICLE	IF	CITATIONS
419	Genomic distribution of signal transducer and activator of transcription (STAT) family in colorectal cancer. <i>Human Cell</i> , 2023, 36, 286-295.	1.2	4
420	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. <i>Biomedicines</i> , 2022, 10, 2628.	1.4	1
421	The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12582.	1.8	4
422	In-depth systems biological evaluation of bovine alveolar macrophages suggests novel insights into molecular mechanisms underlying <i>Mycobacterium bovis</i> infection. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
423	Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. <i>Pharmacological Reviews</i> , 2023, 75, 35-61.	7.1	12
424	Unilateral panuveitis secondary to JAK2 mutation-associated lymphoproliferative disease. <i>BMJ Case Reports</i> , 2022, 15, e253572.	0.2	0
425	The pathogenesis and development of targeted drugs in acute T lymphoblastic leukaemia. <i>British Journal of Pharmacology</i> , 2023, 180, 1017-1037.	2.7	3
426	The JAK-STAT-SOCS Signaling Cascade. , 2016, , 162-179.		0
427	Genetic lesions and targeted therapy in Hodgkin lymphoma. <i>Therapeutic Advances in Hematology</i> , 2023, 14, 204062072211492.	1.1	1
428	JAK inhibitors and autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2023, 22, 103276.	2.5	23
429	Plasmablastic lymphoma: from genetics to treatment. <i>Leukemia and Lymphoma</i> , 2023, 64, 799-807.	0.6	0
430	JAK2 Mutations Are Rare and Diverse in Myelodysplastic Syndromes: Case Series and Review of the Literature. <i>Hematology Reports</i> , 2023, 15, 73-87.	0.3	1
431	Targeting pleckstrin-2/Akt signaling reduces proliferation in myeloproliferative neoplasm models. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	2
432	A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo. <i>Nature Chemical Biology</i> , 2023, 19, 703-711.	3.9	16
433	UPLC-MS/MS method development and application to pharmacokinetic study in rats and dogs of Flonoltinib Maleat. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2023, 1223, 123696.	1.2	3
434	The interplay of signaling pathways with miRNAs in cholangiocarcinoma pathogenicity and targeted therapy. <i>Pathology Research and Practice</i> , 2023, 245, 154437.	1.0	40
435	Discovery of a Potent and Selective STAT5 PROTAC Degradator with Strong Antitumor Activity <i>In Vivo</i> in Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 2717-2743.	2.9	8
436	Tyrosine kinases in nodal peripheral T-cell lymphomas. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2

#	ARTICLE	IF	CITATIONS
437	miRNAs as cornerstones in chronic lymphocytic leukemia pathogenesis and therapeutic resistance— An emphasis on the interaction of signaling pathways. <i>Pathology Research and Practice</i> , 2023, 243, 154363.	1.0	7
438	The critical role of the phytosterols in modulating tumor microenvironment via multiple signaling: A comprehensive molecular approach. <i>Phytotherapy Research</i> , 2023, 37, 1606-1623.	2.8	4
439	Safety of Oral Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis. <i>Dermatitis</i> , 2023, 34, 366-386.	0.8	1
440	BPâ€¹102 exerts antitumor effects on Tâ€¹cell acute lymphoblastic leukemia cells by suppressing the JAK2/STAT3/câ€¹Myc signaling pathway. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	0
441	Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6259.	1.8	1
442	RNA-Seq Profiling between Commercial and Indigenous Iranian Chickens Highlights Differences in Innate Immune Gene Expression. <i>Genes</i> , 2023, 14, 793.	1.0	0
450	Cell-Materials Interaction. <i>Pancreatic Islet Biology</i> , 2023, , 239-258.	0.1	0
451	Small-molecule probes from bench to bedside: advancing molecular analysis of drugâ€¹target interactions toward precision medicine. <i>Chemical Society Reviews</i> , 2023, 52, 5706-5743.	18.7	7
460	Plasmablastic Lymphoma. , 2023, , .		0